Investigating how IgSF11 signaling affects bone loss and osteoclast maturation
IgSF11 Signaling Controls Osteoclast Maturation and Pathogenic Bone Loss
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10987056
This study is looking at how a specific protein called IgSF11 affects the development of bone-resorbing cells, which can help us find better ways to treat conditions that lead to too much bone loss, especially during inflammation.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10987056 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of IgSF11, a cell surface receptor, in the maturation of osteoclasts, which are cells responsible for bone resorption. By examining how IgSF11 signaling influences osteoclast activity under inflammatory conditions, the research aims to develop new therapeutic strategies that target osteoclast maturation rather than just reducing their numbers. The study utilizes animal models to explore the effects of IgSF11 on bone loss and the metabolic pathways involved in osteoclast differentiation. This approach could lead to more effective treatments for conditions that cause excessive bone loss.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing inflammatory bone loss, such as those with conditions like rheumatoid arthritis or osteoporosis.
Not a fit: Patients with non-inflammatory bone loss or those whose bone loss is not related to osteoclast activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that prevent bone loss while preserving bone formation.
How similar studies have performed: Previous research has shown promise in targeting osteoclast maturation, indicating that this approach may lead to significant advancements in treating bone loss.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHOI, YONGWON — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: CHOI, YONGWON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.